Skip to main content

Desipramine

ADVERTISEMENT
Identification
Molecular formula
C18H22N2
CAS number
50-47-5
IUPAC name
3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N-methyl-propan-1-amine
State
State

At room temperature, desipramine is in a solid state. It is usually administered as a hydrochloride salt for pharmaceutical uses.

Melting point (Celsius)
168.00
Melting point (Kelvin)
441.15
Boiling point (Celsius)
408.30
Boiling point (Kelvin)
681.45
General information
Molecular weight
266.38g/mol
Molar mass
266.3840g/mol
Density
1.0560g/cm3
Appearence

Desipramine typically appears as a white to off-white crystalline powder. It is odorless and can absorb moisture from the environment.

Comment on solubility

Solubility of 3-(5,6-Dihydrobenzo[b][1]benzazepin-11-yl)-N-methyl-propan-1-amine

The solubility of the compound with the formula C18H22N2 can be influenced by various factors such as polarity, structure, and the presence of functional groups.

Factors Affecting Solubility:

  • Polarity: This compound contains both hydrophobic (the hydrocarbon chain) and somewhat polar regions (the amine group). This suggests that the compound may have moderate solubility in polar solvents, such as water, while exhibiting higher solubility in organic solvents like ethanol or acetonitrile.
  • Hydrogen Bonding: The presence of nitrogen in the amine group can potentially allow for hydrogen bonding with polar solvents, enhancing solubility.
  • Molecular Weight: With a relatively high molecular weight, solubility may decrease as larger molecules typically face difficulty dispersing in solutions.

In conclusion, while an exact solubility is not determinable without specific experimental data, it is likely that this compound would exhibit:

  • Moderate solubility in polar solvents
  • Higher solubility in non-polar organic solvents

This emphasizes the importance of considering both the molecular structure and the solvent characteristics when predicting solubility for complex compounds like C18H22N2.

Interesting facts

Interesting Facts about 3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N-methyl-propan-1-amine

This intriguing compound, commonly referred to in scientific circles for its potential pharmacological applications, showcases a unique structural architecture that contributes to its biological activities. Here are some notable aspects:

  • Chemical Structure: The compound features a complex structure that includes a dihydrobenzo[b][1]benzazepin moiety. This unique arrangement could influence its interaction with various biological targets.
  • Pharmacological Potential: Researchers have been investigating various derivatives of similar compounds for their potential as therapeutic agents. This compound could offer insights into drug design, particularly in the fields of mental health and neuropharmacology.
  • Synthesis Challenges: The synthesis of such a complex compound can pose significant challenges. Chemists must utilize advanced techniques and strategies to ensure the purity and efficacy of the end product.
  • Interdisciplinary Connections: The study of this compound bridges multiple fields, including medicinal chemistry, neuroscience, and organic synthesis, making it a valuable subject for interdisciplinary research.
  • Research Environment: The exploration of this compound is taking place in various research institutions, indicating its importance in contemporary chemical research and its potential contributions to science.

As scientists continue to unravel the complexities of compounds like 3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N-methyl-propan-1-amine, we may discover not only new therapeutic avenues but also gain a deeper understanding of molecular interactions that govern chemical behavior. It’s an exciting time in the realm of chemistry, where every new find can lead to significant breakthroughs!

Synonyms
desipramine
Norimipramine
50-47-5
Desmethylimipramine
Monodemethylimipramine
Desipramin
Demethylimipramine
Desimipramine
Dimethylimipramine
Dezipramine
Desipramina
Methylaminopropyliminodibenzyl
Imipramine, demethyl-
desipraminum
Desimpramine
DMI (pharmaceutical)
N-(3-Methylaminopropyl)iminobibenzyl
Desipramine (D4)
Norpramine
Pertrofane
Sertofran
3-(10,11-DIHYDRO-5H-DIBENZO[B,F]AZEPIN-5-YL)-N-METHYLPROPAN-1-AMINE
5-(gamma-Methylaminopropyl)iminodibenzyl
DMI 50475
Desipraminum [INN-Latin]
Desipramina [INN-Spanish]
N-desmethylimipramine
Treyzafagit
CCRIS 7091
3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N-methylpropan-1-amine
HSDB 3052
EINECS 200-040-0
Desipramine (INN)
UNII-TG537D343B
BRN 1432747
10,11-Dihydro-5-(3-methylaminopropyl)-5H-dibenz(b,f)azepine
5H-Dibenz(b,f)azepine-5-propanamine, 10,11-dihydro-N-methyl-
CHEBI:47781
TG537D343B
CHEMBL72
5H-Dibenz[b,f]azepine-5-propanamine, 10,11-dihydro-N-methyl-
DTXSID6022896
5H-Dibenz(b,f)azepine, 10,11-dihydro-5-(3-(methylamino)propyl)-
DESIPRAMINE [INN]
Desipraminum (INN-Latin)
Desipramina (INN-Spanish)
Desipramine [INN:BAN]
10,11-dihydro-5-(3-(methylamino)propyl)-5h-dibenz(b,f)azepine
Desmethylimipramine;Imipramine,demethyl-;Methylaminopropyliminodibenzyl
CAS-58-28-6
NCGC00015340-02
5H-Dibenz[b,f]azepine, 10,11-dihydro-5-[3-(methylamino)propyl]-
3-(10,11-dihydro-5H-dibenzo(b,f)azepin-5-yl)-N-methylpropan-1-amine
Imipramine-M Nor
Desipramine;Norpramin
Desipramine Free Base
(3-(10H,11H-Dibenzo[b,f]azepin-5-yl)propyl)methylamine
Pertofran (Salt/Mix)
Spectrum_000441
Pertofrane (Salt/Mix)
3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N-methylpropan-1-amine hydrochloride
IMIPRAMINE_met001
DESIPRAMINE [MI]
Prestwick0_000343
Prestwick1_000343
Prestwick2_000343
Prestwick3_000343
Spectrum2_000091
Spectrum3_000379
Spectrum4_000314
Spectrum5_000833
Lopac-D-3900
DESIPRAMINE [HSDB]
DESIPRAMINE [VANDF]
Lopac0_000358
SCHEMBL34384
BSPBio_000405
BSPBio_002137
DESIPRAMINE [WHO-DD]
KBioGR_000928
KBioSS_000921
DivK1c_000190
SPBio_000042
SPBio_002326
BPBio1_000447
DTXCID902896
GTPL2399
BDBM35229
HY-B1272A
KBio1_000190
KBio2_000921
KBio2_003489
KBio2_006057
KBio3_001357
N06AA01
NINDS_000190
10, 11-Dihydro-N-methyl-5H-dibez[b,f]azepine-5-propanamine
HMS3430H03
HMS3742I19
ALBB-025959
3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N-methyl-propan-1-amine
STK735144
AKOS001681456
CCG-118231
CS-8193
DB01151
SDCCGSBI-0050346.P005
IDI1_000190
NCGC00015340-01
NCGC00015340-03
NCGC00015340-04
NCGC00015340-05
NCGC00015340-06
NCGC00015340-07
NCGC00015340-08
NCGC00015340-09
NCGC00015340-10
NCGC00015340-11
NCGC00015340-13
NCGC00015340-22
NCGC00024375-04
AC-15977
SBI-0050346.P004
AB00053450
NS00010406
C06943
D07791
AB00053450_14
EN300-18293453
L001089
Q423288
BRD-K60762818-003-15-3
BRD-K60762818-003-25-2
BRD-K60762818-003-26-0
IMIPRAMINE HYDROCHLORIDE IMPURITY A [EP IMPURITY]
5-(3-methylaminopropyl)-10,11-dihydro-5H-dibenzo[b,f]azepine
5H-Dibenz[b,f]azepine, 10,11-dihydro-5-(methylamino)propyl-
5H-Dibenzo[b, f]azepine, N-(3-methylaminopropyl)-, 10,11-Dihydro
3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-N-methyl-1-propanamine #
N-[3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)propyl]-N-methylamine
(3-{2-azatricyclo[9.4.0.0,3,8]pentadeca-1(15),3,5,7,11,13-hexaen-2-yl}propyl)(methyl)amine
(3-{2-azatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3(8),4,6,12,14-hexaen-2-yl}propyl)(methyl)amine
200-040-0